A randomized evaluation of the reversal of ketamine by physostigmine.
One hundred and eleven patients undergoing ketamine anaesthesia for therapeutic abortion were studied in a double-blind trial of the reversal of ketamine by physostigmine administered postoperatively. The results demonstrate that physostigmine does not shorten recovery time or reduce the occurrence of ketamine emergence phenomena such as hallucinations, restlessness and dreams. In fact, the recovery course was prolonged in patients given physostigmine immediately upon termination of anaesthesia as compared with controls. By contrast, when physostigmine was given 30 minutes after the last dose of ketamine, the recovery was not prolonged as compared with that of the placebo-treated controls. These findings suggest some synergism between the effects of ketamine and physostigmine and should discourage the use of physostigmine as a ketamine antidote.
D000032:Abortion, Therapeutic; D000293:Adolescent; D000328:Adult; D000771:Anesthesia, Intravenous; D000773:Anesthesia, Obstetrical; D003243:Consciousness / Q000187:drug effects; D004311:Double-Blind Method; D004325:Dreams / Q000187:drug effects; D005260:Female; D006801:Humans; D007649:Ketamine / Q000037:antagonists & inhibitors*; D009949:Orientation / Q000187:drug effects; D010830:Physostigmine / Q000494:pharmacology*; D010919:Placebos; D011247:Pregnancy; D011997:Recovery Room; D013997:Time Factors
D010919:Placebos; D007649:Ketamine; D010830:Physostigmine